ABCG2 Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban.

Hamin KimTae Jin SongJeong YeeDong-Hyeok KimJunbeom Park Hye Sun Gwak

Published in: Drug design, development and therapy (2023)

rs1045642 were significantly associated with the risk of bleeding complications in patients on apixaban and rivaroxaban, after adjusting for other confounders. These findings can be used to develop individualized treatment strategies for patients taking apixaban and rivaroxaban.

Keyphrases

atrial fibrillation
end stage renal disease
venous thromboembolism
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
risk factors